HOME PAGE

Primary Pulmonary Hypertension (PPH) Common Symptoms
-Shortness of breath
-Chest pain
-Weakness
-New Heart Murmur
-Fatigue
-Fainting
-Tiredness
-Death

The New England Journal of Medicine 1996 study found:
Primary Pulmonary Hypertension (PPH) occurs in 1 in 500,000 people normally but occurs in 1 in 20,000 fen phen users. It is estimated that between 6 million and 7 million people in the U.S. have taken fen phen.

Controversy
::::::::::::::::::::

American Home Products (AHP), fen phen manufacturer, knew about the testing in Europe that found the diet drugs to cause primary pulmonary hypertension (PPH). Despite this knowledge, AHP did not list PPH under the 'adverse reaction' area of the drug's label. The labels on the fen phen bottles were not changed until the number of fatalities reached 62 due to PPH. The FDA later found AHP had miscoded PPH reports, in addition to failing to have an official medical monitor in 1995.

Allegations of Fen Phen Cover-Up
American Home Products (AHP) has been accused of covering up problems with fen phen that emerged during FDA testing according to a former FDA scientist. Dr. Leo Lutwak told CBS News in April 2000 that the company knew about problems long before the 1997 fen phen withdrawal. Lutwak claims that AHP contorted his research to make it appear that they had no way of predicting the dangerous health complications fen phen causes. Because the FDA would not let Lutwak testify, the former FDA scientist told CBS he was planning on retiring in order to make him available to testify.
ATTENTION
PPH PATIENTS
Patients suffering from Primary Pulmonary Hypertension (PPH) caused by Fen-Phen are NOT involved in the Nationwide Class Action Settlement Agreement with American Home Products. PPH patients must file independent lawsuits to make legal claims. To learn your legal rights, please contact us and speak with a PPH Lawyer for lawsuit information!

FEN PHEN CLAIMS DEADLINE:
AUGUST 2002
Numerous former fen phen patients are now suffering the serious and fatal condition called primary pulmonary hypertension (PPH). An estimated 6 million to 7 million people in the U.S. have taken fen phen. On January 11, 2002 the fen phen Settlement became final. If you have used the diet drug fen phen, also marketed under the names Redux and Pondimin, you are eligible to file a claim by August 2002. CONTACT US so that you can receive the compensation that is rightfully yours.

FDA Withdrawal of Fenfluramine and Dexfenfluramine (Fen Phen) Announcement

FOR IMMEDIATE RELEASE
September 15, 1997

FDA ANNOUNCES WITHDRAWAL OF FENFLURAMINE AND DEXFENFLURAMINE

The Food and Drug Administration, acting on new evidence about significant side-effects associated with fenfluramine and dexfenfluramine, has asked the manufacturers to voluntarily withdraw both treatments for obesity from the market. Dexfenfluramine is manufactured for Interneuron Pharmaceuticals and marketed under the name of Redux by Wyeth-Ayerst Laboratories, a subsidiary of American Home Products Corp. of Madison, N.J., which also manufactures and markets fenfluramine under the brand name Pondimin. Both companies have agreed to voluntarily withdraw their drugs. The FDA is not requesting the withdrawal of phentermine, the third widely used medication for obesity.
read the full story >

top of page

Fen Phen Settlement

American Home Products (AHP) withdrew popular diet drug fen phen from the market on September 15, 1997. The once deemed "miracle drug" took off with an immediate 18,000,000 prescriptions written in 1996 and in the U.S. there are estimates that between 6 million and 7 million people took fen phen.

Fen phen did not live up to its name, though, as reports of a serious and fatal condition called primary pulmonary hypertension (PPH) began to surface. But evidence of the serious and fatal health complications fen phen could cause were available well prior to the FDA withdrawal. In a 1996 study published in The New England Journal of Medicine, it concluded that there is a twenty-three-fold increase in the risk of developing PPH when using fen phen for more than three months.
read the full story >

top of page

Nationwide Class Action Settlement Agreement
:::::::::::::::::::::::::::::::::
American Home Products Corporation has received Final Judicial Approval as of January 3, 2002 regarding their once popular diet drug fen phen. This settlement has beenthe result of the serious health complications fen phen use has been directly linked to like primary pulmonary hypertension (PPH).

Primary pulmonary hypertension is a serious and potentially life threatening cardiovascular condition, and a 1996 study published in The New England Journal of Medicine found a twenty-three-fold increase in the risk of developing PPH when using fen phen for more than three months. In 1996 alone there were 18,000,000 prescriptions written for the appetite suppressant fen phen, and in the U.S. there are estimates that between 6 million and 7 million people took fen phen.

Final judicial approval means that anyone who has sustained the deadly phentermine side effects can now collect their claims if eligible. Please contact us for more information regarding your benefit eligibility and to speak to a PPH attorney.

top of page

About Primary Pulmonary Hypertension (PPH)

"It's a very rare disease (PPH), that tends to affect women in their 30s. After diagnosis, patients are typically dead within two years."
-Dr. Sean Gaine, director of the pulmonary hypertension center at John Hopkins Medical Center in Boston.

Primary pulmonary hypertension (PPH) is a serious and potentially life threatening cardiovascular condition that is not curable. A study published in the New England Journal of Medicine in August 1996 found that the use of fen phen for three months or longer is associated with a twenty-three fold increase in the risk of developing primary pulmonary hypertension. PPH causes high blood pressure in the lungs that leads to a feeling of constant breathlessness with minimal exertion, fatigue, dizzy spells, fainting, and chest pain. There is no known cause of PPH but it has been the direct result of the use of the once popular diet drug fen phen, or phentermine.
read the full story >

top of page

Fen Phen Information

Dr. Michael Weintraub developed fen phen while working as a researcher at the University of Rochester. The phentermine and pondimin combination in a low dose was found to suppress appetite to fuel weight loss and have fewer side effects then when the drugs were taken individually. The weight loss drug combination was termed fen phen, and the drug's popularity was immediate. In 1996 alone there were 18,000,000 prescriptions written for the appetite suppressant fen phen.
read the full story >

top of page







Quotes
:::::::::::::::::::::::::::::::::

"I couldn't walk more than a couple of feet without having to stop and catch my breath. I asked him (Dr. Lewis Rubin of the U of Maryland) what the prognosis was and he said that without medication, my life expectancy was about two years."
-Andrea Adams, former fen phen user who now suffers the fatal disease PPH. Adams began to notice PPH symptoms just 18 months after beginning fen phen
(CNN, 12-96)

"We had been concerned about PPH links to these drugs for years, but that was lost amid all the scuffle about the heart valve disease. That came out of the blue. No one was expecting it. There are two issues here because there's a big difference between the heart valve problems and pulmonary hypertension. The heart valve problem is bad, but at least it's something there's a cure for. You can replace the valve if you get it in time and so forth, but there's no cure for pulmonary hypertension."
-Dr. Sean Gaine, director of the pulmonary hypertension center at John Hopkins Medical Center in Boston.

"I felt from the very beginning the drug companies (American Home Products) were covering up. I felt from the very beginning that these drugs (fen phen) were dangerous.
-Dr. Leo Lutwak, former FDA key reviewer of fen phen
(CBS 4-00)